Table 2.

Relationships between TPL2 and Pin1 expression with clinicopathological parameters in IDC.

	n	TPL2			Pin1
		≥ 150	χ2	P	≥ 150	χ2	P
Age
< 50 years	31	19 (61.3%)	0.306	0.58	16 (51.6%)	0.235	0.628
≥ 50 years	49	33 (67.3%)			28 (57.1%)
Tumor size
≤ 2 cm	26	20 (76.9%)	2.407	0.121	16 (61.5%)	0.665	0.415
> 2 cm	54	32 (59.3%)			28 (51.9%)
Histological grade
1–2	50	37 (74%)	4.747	0.029	30 (60%)	1.347	0.246
3	30	15 (50%)			14 (46.7%)
Lymph node metastasis
Yes	48	29 (60.4%)	1.108	0.293	24 (50%)	1.212	0.271
No	32	23 (71.9%)			20 (62.5%)
TNM stage
I	16	14 (87.5%)	4.451	0.035	11 (68.8%)	1.528	0.216
II–III	64	38 (59.4%)			33 (51.6%)
ER
+	49	35 (71.4%)	2.297	0.13	32 (65.3%)	5.427	0.02
-	31	17 (54.8%)			12 (38.7%)
PR
+	37	27 (73.0%)	1.923	0.165	24 (64.9%)	2.707	0.100
-	43	25 (58.1%)			20 (46.5%)

TPL2, tumor progression locus 2; Pin1, peptidyl-prolyl cis–trans isomerase 1; TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor.

*Pearson’s chi-square test.

Significant are in value bold.